Processa Pharmaceuticals Inc (PCSA)

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing cancer therapies intended to improve the safety and effectiveness of oncology treatment in the United States. Its approach centers on modifying existing FDA-approved cancer drugs to change how they are metabolized or distributed while preserving their cancer-killing activity.

The company’s oncology pipeline includes NGC-Cap (PCS6422), a combination therapy in Phase 2 testing for metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors, as well as NGC-Iri (PCS11T), a preclinical irinotecan-related candidate being studied across several cancer types. Processa also develops non-oncology programs, including PCS499, which has completed a Phase 2b trial in primary glomerular diseases and ulcerative necrobiosis lipoidica, and PCS12852, which has completed a Phase 2 trial for gastroparesis and constipation disorders. The company has licensing agreements with Elion Oncology, Aposense, Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Founded in 2015, Processa Pharmaceuticals is based in Vero Beach, Florida.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.